Consensus statement: Cardiovascular safety profile of triptans (5-HT 1B/1D agonists) in the acute treatment of migraine

David Dodick, Richard B. Lipton, Vincent Martin, Vasilios Papademetriou, Wayne Rosamond, Antoinette Maassen VanDenBrink, Hassan Loutfi, K. Michael Welch, Peter J. Goadsby, Steven Hahn, Susan Hutchinson, David Matchar, Stephen Silberstein, Timothy R. Smith, R. Allan Purdy, Jane Saiers

Research output: Contribution to journalArticle

225 Citations (Scopus)

Abstract

Background. - Health care providers frequently cite concerns about cardiovascular safety of the triptans as a barrier to their use. In 2002, the American Headache Society convened the Triptan Cardiovascular Safety Expert Panel to evaluate the evidence on triptan-associated cardiovascular risk and to formulate consensus recommendations for making informed decisions for their use in patients with migraine. Objective. - To summarize the evidence reviewed by the Triptan Cardiovascular Safety Expert Panel and their recommendations for the use of triptans in clinical practice. Participants. - The Triptan Cardiovascular Safety Expert Panel was composed of a multidisciplinary group of experts in neurology, primary care, cardiology, pharmacology, women's health, and epidemiology. Evidence and Consensus Process. - An exhaustive search of the relevant published literature was reviewed by each panel member in preparation for an open roundtable meeting. Pertinent issues (eg, cardiovascular pharmacology of triptans, epidemiology of cardiovascular disease, cardiovascular risk assessment, migraine) were presented as a prelude to group discussion and formulation of consensus conclusions and recommendations. Follow-up meetings were held by telephone. Conclusions. - (1) Most of the data on triptans are derived from patients without known coronary artery disease. (2) Chest symptoms occurring during use of triptans are generally nonserious and are not explained by ischemia. (3) The incidence of serious cardiovascular events with triptans in both clinical trials and clinical practice appears to be extremely low. (4) The cardiovascular risk-benefit profile of triptans favors their use in the absence of contraindications.

Original languageEnglish (US)
Pages (from-to)414-425
Number of pages12
JournalHeadache
Volume44
Issue number5
DOIs
StatePublished - May 2004

Fingerprint

Tryptamines
Migraine Disorders
Serotonin
Consensus
Safety
Therapeutics
Epidemiology
Pharmacology
Women's Health
Neurology
Cardiology
Telephone
Health Personnel
Coronary Artery Disease
Primary Health Care
Decision Making
Cardiovascular Diseases
Thorax
Ischemia

Keywords

  • Consensus statement
  • Headache
  • Migraine
  • Triptans

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Consensus statement : Cardiovascular safety profile of triptans (5-HT 1B/1D agonists) in the acute treatment of migraine. / Dodick, David; Lipton, Richard B.; Martin, Vincent; Papademetriou, Vasilios; Rosamond, Wayne; VanDenBrink, Antoinette Maassen; Loutfi, Hassan; Welch, K. Michael; Goadsby, Peter J.; Hahn, Steven; Hutchinson, Susan; Matchar, David; Silberstein, Stephen; Smith, Timothy R.; Purdy, R. Allan; Saiers, Jane.

In: Headache, Vol. 44, No. 5, 05.2004, p. 414-425.

Research output: Contribution to journalArticle

Dodick, D, Lipton, RB, Martin, V, Papademetriou, V, Rosamond, W, VanDenBrink, AM, Loutfi, H, Welch, KM, Goadsby, PJ, Hahn, S, Hutchinson, S, Matchar, D, Silberstein, S, Smith, TR, Purdy, RA & Saiers, J 2004, 'Consensus statement: Cardiovascular safety profile of triptans (5-HT 1B/1D agonists) in the acute treatment of migraine', Headache, vol. 44, no. 5, pp. 414-425. https://doi.org/10.1111/j.1526-4610.2004.04078.x
Dodick, David ; Lipton, Richard B. ; Martin, Vincent ; Papademetriou, Vasilios ; Rosamond, Wayne ; VanDenBrink, Antoinette Maassen ; Loutfi, Hassan ; Welch, K. Michael ; Goadsby, Peter J. ; Hahn, Steven ; Hutchinson, Susan ; Matchar, David ; Silberstein, Stephen ; Smith, Timothy R. ; Purdy, R. Allan ; Saiers, Jane. / Consensus statement : Cardiovascular safety profile of triptans (5-HT 1B/1D agonists) in the acute treatment of migraine. In: Headache. 2004 ; Vol. 44, No. 5. pp. 414-425.
@article{99aada68eaa34e679dc9eb1f536bc486,
title = "Consensus statement: Cardiovascular safety profile of triptans (5-HT 1B/1D agonists) in the acute treatment of migraine",
abstract = "Background. - Health care providers frequently cite concerns about cardiovascular safety of the triptans as a barrier to their use. In 2002, the American Headache Society convened the Triptan Cardiovascular Safety Expert Panel to evaluate the evidence on triptan-associated cardiovascular risk and to formulate consensus recommendations for making informed decisions for their use in patients with migraine. Objective. - To summarize the evidence reviewed by the Triptan Cardiovascular Safety Expert Panel and their recommendations for the use of triptans in clinical practice. Participants. - The Triptan Cardiovascular Safety Expert Panel was composed of a multidisciplinary group of experts in neurology, primary care, cardiology, pharmacology, women's health, and epidemiology. Evidence and Consensus Process. - An exhaustive search of the relevant published literature was reviewed by each panel member in preparation for an open roundtable meeting. Pertinent issues (eg, cardiovascular pharmacology of triptans, epidemiology of cardiovascular disease, cardiovascular risk assessment, migraine) were presented as a prelude to group discussion and formulation of consensus conclusions and recommendations. Follow-up meetings were held by telephone. Conclusions. - (1) Most of the data on triptans are derived from patients without known coronary artery disease. (2) Chest symptoms occurring during use of triptans are generally nonserious and are not explained by ischemia. (3) The incidence of serious cardiovascular events with triptans in both clinical trials and clinical practice appears to be extremely low. (4) The cardiovascular risk-benefit profile of triptans favors their use in the absence of contraindications.",
keywords = "Consensus statement, Headache, Migraine, Triptans",
author = "David Dodick and Lipton, {Richard B.} and Vincent Martin and Vasilios Papademetriou and Wayne Rosamond and VanDenBrink, {Antoinette Maassen} and Hassan Loutfi and Welch, {K. Michael} and Goadsby, {Peter J.} and Steven Hahn and Susan Hutchinson and David Matchar and Stephen Silberstein and Smith, {Timothy R.} and Purdy, {R. Allan} and Jane Saiers",
year = "2004",
month = "5",
doi = "10.1111/j.1526-4610.2004.04078.x",
language = "English (US)",
volume = "44",
pages = "414--425",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Consensus statement

T2 - Cardiovascular safety profile of triptans (5-HT 1B/1D agonists) in the acute treatment of migraine

AU - Dodick, David

AU - Lipton, Richard B.

AU - Martin, Vincent

AU - Papademetriou, Vasilios

AU - Rosamond, Wayne

AU - VanDenBrink, Antoinette Maassen

AU - Loutfi, Hassan

AU - Welch, K. Michael

AU - Goadsby, Peter J.

AU - Hahn, Steven

AU - Hutchinson, Susan

AU - Matchar, David

AU - Silberstein, Stephen

AU - Smith, Timothy R.

AU - Purdy, R. Allan

AU - Saiers, Jane

PY - 2004/5

Y1 - 2004/5

N2 - Background. - Health care providers frequently cite concerns about cardiovascular safety of the triptans as a barrier to their use. In 2002, the American Headache Society convened the Triptan Cardiovascular Safety Expert Panel to evaluate the evidence on triptan-associated cardiovascular risk and to formulate consensus recommendations for making informed decisions for their use in patients with migraine. Objective. - To summarize the evidence reviewed by the Triptan Cardiovascular Safety Expert Panel and their recommendations for the use of triptans in clinical practice. Participants. - The Triptan Cardiovascular Safety Expert Panel was composed of a multidisciplinary group of experts in neurology, primary care, cardiology, pharmacology, women's health, and epidemiology. Evidence and Consensus Process. - An exhaustive search of the relevant published literature was reviewed by each panel member in preparation for an open roundtable meeting. Pertinent issues (eg, cardiovascular pharmacology of triptans, epidemiology of cardiovascular disease, cardiovascular risk assessment, migraine) were presented as a prelude to group discussion and formulation of consensus conclusions and recommendations. Follow-up meetings were held by telephone. Conclusions. - (1) Most of the data on triptans are derived from patients without known coronary artery disease. (2) Chest symptoms occurring during use of triptans are generally nonserious and are not explained by ischemia. (3) The incidence of serious cardiovascular events with triptans in both clinical trials and clinical practice appears to be extremely low. (4) The cardiovascular risk-benefit profile of triptans favors their use in the absence of contraindications.

AB - Background. - Health care providers frequently cite concerns about cardiovascular safety of the triptans as a barrier to their use. In 2002, the American Headache Society convened the Triptan Cardiovascular Safety Expert Panel to evaluate the evidence on triptan-associated cardiovascular risk and to formulate consensus recommendations for making informed decisions for their use in patients with migraine. Objective. - To summarize the evidence reviewed by the Triptan Cardiovascular Safety Expert Panel and their recommendations for the use of triptans in clinical practice. Participants. - The Triptan Cardiovascular Safety Expert Panel was composed of a multidisciplinary group of experts in neurology, primary care, cardiology, pharmacology, women's health, and epidemiology. Evidence and Consensus Process. - An exhaustive search of the relevant published literature was reviewed by each panel member in preparation for an open roundtable meeting. Pertinent issues (eg, cardiovascular pharmacology of triptans, epidemiology of cardiovascular disease, cardiovascular risk assessment, migraine) were presented as a prelude to group discussion and formulation of consensus conclusions and recommendations. Follow-up meetings were held by telephone. Conclusions. - (1) Most of the data on triptans are derived from patients without known coronary artery disease. (2) Chest symptoms occurring during use of triptans are generally nonserious and are not explained by ischemia. (3) The incidence of serious cardiovascular events with triptans in both clinical trials and clinical practice appears to be extremely low. (4) The cardiovascular risk-benefit profile of triptans favors their use in the absence of contraindications.

KW - Consensus statement

KW - Headache

KW - Migraine

KW - Triptans

UR - http://www.scopus.com/inward/record.url?scp=2542502483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542502483&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4610.2004.04078.x

DO - 10.1111/j.1526-4610.2004.04078.x

M3 - Article

C2 - 15147249

AN - SCOPUS:2542502483

VL - 44

SP - 414

EP - 425

JO - Headache

JF - Headache

SN - 0017-8748

IS - 5

ER -